Education
About Us
Working with TipRanks
Follow Us
Siga Technologies (SIGA)
:SIGA
Top Page
SIGA Technologies
(NASDAQ:SIGA)
Rating:81Outperform
Price Target:
$6.50
▲(4.50%Upside)
SIGA Technologies (SIGA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$444.36M
Dividend Yield10.13%
Average Volume (3M)448.80K
Price to Earnings (P/E)9.2
Beta (1Y)0.93
Revenue Growth-23.37%
EPS Growth-39.03%
CountryUS
Employees46
SectorHealthcare
Sector Strength41
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding71,441,086
10 Day Avg. Volume415,135
30 Day Avg. Volume448,798
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio7.00
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue0.45
Enterprise Value/Gross Profit3.18
Enterprise Value/Ebitda0.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
SIGA Technologies Business Overview & Revenue Model
Company DescriptionSIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
How the Company Makes MoneySIGA Technologies generates revenue primarily through government contracts and sales of its antiviral products. A significant portion of its income is derived from contracts with the U.S. government, particularly through the Biomedical Advanced Research and Development Authority (BARDA) for the procurement of TPOXX to maintain the national stockpile for biodefense. Additionally, SIGA benefits from international government contracts and collaborations with global health organizations seeking to bolster their emergency preparedness. The company may also earn from licensing agreements and future expansion of its product line for commercial markets.
SIGA Technologies Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: 14.34%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Positive
SIGA Technologies presented a strong performance in international business expansion, significant U.S. government orders, and robust financial health, despite some operational losses and uncertainties in contract timelines. The company's strategic initiatives and shareholder returns indicate a positive outlook.Q1-2025 Updates
Positive Updates
International Business Expansion
SIGA achieved product revenues of approximately $6 million due to a sale to a repeat international customer in a new geographical region, signaling the broadened scope of their international business.
U.S. Government TPOXX Orders
Approximately $53 million of oral TPOXX and $9 million of IV TPOXX were delivered to the U.S. Strategic National Stockpile in April. Additionally, the U.S. government exercised an option to procure an additional $26 million of IV TPOXX, with delivery expected in 2026.
Regulatory Approvals and Pipeline Progress
TPOXX received regulatory approvals in Japan, in addition to existing approvals in the U.S., Canada, Europe, and the U.K. The PEP program is progressing with the FDA's guidance, aiming for a submission in the first half of 2026.
Financial Stability and Shareholder Returns
SIGA declared a special cash dividend of $0.60 per share, demonstrating the strength of the balance sheet and confidence in the company's future.
Strong Balance Sheet
As of March 31, 2025, SIGA had a cash balance of approximately $162 million and no debt, indicating a strong financial position.
Negative Updates
Operating Loss
SIGA reported a pretax operating loss of approximately $2 million for the first quarter, with a net loss of approximately $1 million.
Uncertain RFP Timeline
There is uncertainty around the timeline for the Request for Proposal (RFP) for a new TPOXX contract due to recent policy changes in the U.S. government.
Company Guidance
During SIGA Technologies' business update call for the first quarter of 2025, CEO Diem Nguyen reported product revenues of approximately $6 million, driven by an international sale to a repeat customer. The company has regulatory approvals for TPOXX in multiple regions, including the U.S., Canada, Europe, the U.K., and Japan, and anticipates substantial sales in the coming months. SIGA delivered about $62 million worth of TPOXX to the U.S. Strategic National Stockpile in April, and the U.S. government exercised a $26 million procurement option for IV TPOXX, with additional funding of $14 million for manufacturing activities over the next 2-3 years. The company continues to advance its pipeline, targeting an FDA submission for the PEP indication in the first half of 2026. Financially, SIGA ended the quarter with a cash balance of $162 million and no debt, and declared a special cash dividend of $0.60 per share, reflecting its strong balance sheet and future confidence.SIGA Technologies Financial Statement Overview
Summary
SIGA Technologies exhibits strong financial health characterized by high profitability, a robust balance sheet with no debt, and sufficient cash flow generation. The company demonstrates excellent cost control and capital management. However, stagnant revenue growth and a decline in operating cash flow are areas to monitor closely for future financial performance.Income Statement
SIGA Technologies has shown strong profitability with consistent gross and net profit margins over the years. The gross profit margin remains high at 100% in the latest year, indicating effective cost management. The net profit margin, although slightly reduced from the previous year, is still robust at 42.7%. However, the revenue growth has been stagnant, with a slight decrease of 0.9% from the prior year, which could suggest a plateau in sales expansion.85
Very Positive
Balance Sheet
The company maintains a solid financial position with no debt, reflected in a debt-to-equity ratio of 0. The equity ratio is strong at 88.3%, indicating financial stability and a low-risk profile. Return on equity (ROE) is healthy at 27.4%, showcasing effective use of equity financing to generate profits. The absence of debt reduces financial risk significantly.88
Very Positive
Cash Flow
Operating cash flow has decreased by 48.6% compared to the previous year, which could be a concern if the trend continues. However, free cash flow remains positive, indicating the company can cover its capital expenditures. The free cash flow to net income ratio is satisfactory, showing that profits are backed by cash generation. The decline in cash flow growth rate is a potential risk area.78
Positive
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 120.33M | 138.72M | 139.92M | 110.78M | 133.67M | 124.96M | Gross Profit |
| 85.30M | 95.12M | 122.09M | 77.82M | 107.13M | 99.22M | EBIT |
| 56.45M | 69.98M | 83.62M | 42.70M | 89.09M | 84.50M | EBITDA |
| 56.86M | 70.52M | 84.16M | 43.22M | 89.62M | 85.03M | Net Income Common Stockholders |
| 48.53M | 59.21M | 68.07M | 33.90M | 69.45M | 56.34M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 162.27M | 155.40M | 150.15M | 98.79M | 103.14M | 117.89M | Total Assets |
| 247.07M | 244.34M | 254.35M | 195.04M | 214.73M | 149.83M | Total Debt |
| 558.65K | 546.82K | 564.01K | 528.17K | 466.83K | 449.94K | Net Debt |
| -161.71M | -154.85M | -149.58M | -98.26M | -102.67M | -117.44M | Total Liabilities |
| 30.93M | 28.53M | 57.49M | 24.88M | 40.41M | 20.04M | Stockholders Equity |
| 216.13M | 215.80M | 196.86M | 170.16M | 174.31M | 129.79M |
| Cash Flow | Free Cash Flow | ||||
| 61.87M | 48.72M | 94.78M | 41.61M | 11.44M | 71.50M | Operating Cash Flow |
| 61.94M | 48.76M | 94.80M | 41.61M | 11.49M | 71.52M | Investing Cash Flow |
| -67.34K | -42.45K | -21.69K | 0.00 | -50.62K | -15.50K | Financing Cash Flow |
| -43.47M | -43.46M | -43.42M | -45.96M | -26.20M | -114.60M |
SIGA Technologies Technical Analysis
Positive
6.22
Price Trends
5.64
Positive
5.48
Positive
5.94
Positive
Market Momentum
0.12
Positive
55.11
Neutral
40.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGA, the sentiment is Positive. The current price of 6.22 is above the 20-day moving average (MA) of 6.03, above the 50-day MA of 5.64, and above the 200-day MA of 5.94, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 55.11 is Neutral, neither overbought nor oversold. The STOCH value of 40.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SIGA.
SIGA Technologies Risk Analysis
SIGA Technologies disclosed 39 risk factors in its most recent earnings report. SIGA Technologies reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SIGA Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $444.36M | 9.16 | 25.47% | 10.13% | -23.37% | -39.03% | |
56 Neutral | $366.38M | ― | -21.63% | ― | -18.56% | 76.88% | |
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% | |
53 Neutral | $1.45B | ― | -20.41% | ― | 0.45% | -125.61% | |
44 Neutral | $355.59M | ― | 77.48% | ― | 5.29% | -37.31% | |
43 Neutral | $384.37M | 928.57 | -4.92% | ― | 5.35% | -432.51% |
* Healthcare Sector Average
Performance Comparison
SIGA
SIGA Technologies
6.22
-0.92
-12.89%
EBS
Emergent Biosolutions
6.75
0.43
6.80%
EVO
Evotec AG
4.13
-0.69
-14.32%
ORGO
Organogenesis Holdings
3.47
0.83
31.44%
AQST
Aquestive Therapeutics
3.58
0.77
27.40%
SIGA Technologies Corporate Events
Executive/Board Changes
SIGA Technologies Appoints Gen. Keane as New Director
Positive
Mar 18, 2025
On March 17, 2025, SIGA Technologies appointed General John M. ‘Jack’ Keane (Ret.) as a director, effective immediately. Gen. Keane received stock options and an annual retainer, with his appointment aligning with Nasdaq’s independence requirements, potentially strengthening the company’s governance and strategic direction.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.